Kamada (NASDAQ:KMDA) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Kamada (NASDAQ:KMDA) announced its earnings results on Monday. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01, FiscalAI reports. The business had revenue of $52.03 million for the quarter, compared to analysts’ expectations of $52.51 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Here are the key takeaways from Kamada’s conference call:

• Positive Sentiment: Kamada raised 2026 guidance to $205 million–$208 million in revenue and $52 million–$54 million in adjusted EBITDA. Management also expects another year of double-digit revenue and profitability growth in 2027.
• Positive Sentiment: Nine-month revenue rose 12% to $152.2 million, adjusted EBITDA increased 20% to $40.9 million, and net income grew 29% to $21.4 million. Operating cash flow more than doubled year over year to $37.6 million.
• Positive Sentiment: Demand for KEDRAB remains strong in the U.S. and international markets; management said Kedrion is ordering above its minimum commitment and Kamada has capacity to support further growth. The company expects the demand trend to continue beyond 2026.
• Positive Sentiment: Distribution revenue grew 35% in the first nine months, supported by new biosimilar launches in Israel and expansion into the MENA region. Kamada projects biosimilar revenue of about $10 million in 2028 and $20 million–$25 million by 2030, with at least two more launches planned for 2027.
• Neutral Sentiment: Kamada announced a three-year, approximately $50 million plasma supply agreement, with initial sales expected in the fourth quarter and already included in 2026 guidance. Management noted that benefits from using its own collected plasma in manufacturing have not yet been reflected in results.

Kamada Price Performance

NASDAQ KMDA opened at $7.71 on Tuesday. The stock has a market capitalization of $443.40 million, a P/E ratio of 20.29, a P/E/G ratio of 0.62 and a beta of 0.90. The business has a 50 day simple moving average of $8.07 and a 200 day simple moving average of $8.00. Kamada has a one year low of $6.59 and a one year high of $9.35.

Kamada Dividend Announcement

The firm also recently announced a special dividend, which will be paid on Wednesday, December 9th. Investors of record on Thursday, November 19th will be paid a dividend of $0.14 per share. The ex-dividend date of this dividend is Thursday, November 19th. Kamada’s dividend payout ratio (DPR) is currently 34.21%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on KMDA shares. Stifel Nicolaus set a $12.00 price target on shares of Kamada in a research report on Monday. Weiss Ratings upgraded shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. Benchmark reiterated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Finally, William Blair set a $15.00 target price on shares of Kamada in a report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $13.75.

Kamada News Roundup

Here are the key news stories impacting Kamada this week:

• Positive Sentiment: Kamada reported third-quarter earnings of $0.14 per share, beating the $0.13 analyst consensus and rising from $0.09 a year earlier. The company also reported record-high results for the first nine months of 2026. Company results and outlook
• Positive Sentiment: The company raised its 2026 revenue guidance to $205 million–$208 million and projected double-digit revenue and profitability growth in 2027, signaling confidence in its outlook. Company results and outlook
• Positive Sentiment: Kamada secured a three-year, $50 million agreement to supply U.S. source plasma, supporting its supply position and potential growth. Plasma supply deal report
• Positive Sentiment: The company declared a $0.14-per-share special dividend, payable December 9 to shareholders of record November 19. Dividend announcement
• Positive Sentiment: Stifel raised its price target on KMDA to $12, adding an additional positive analyst signal. Stifel price target report
• Negative Sentiment: Third-quarter revenue of $52.03 million came in slightly below analysts’ $52.51 million estimate, tempering the earnings beat. Quarterly earnings report

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.